Penn's Renal-Electrolyte and Hypertension Division

View the clinical trials currently available for candidates with glomerular disease.

Cure GN (For patient with minimal change disease, FSGS, IgA nephropathy and membranous nephropathy)

  • Name of PI and Coordinator or Recruiter:
    • Lawrence B. Holzman, MD
    • Jonathan Hogan, MD
    • Radhakrishna Kallem, MD, MPH
  • Contact:
    Krishna Kallem
    krishna.kallem@uphs.upenn.edu
    484-358-0315
  • Type of Study:
    Observational
  • Purpose of Study/Patient Population:
    The Cure Glomerulopathy Network (Cure GN) is a multi-disciplinary, multi-center longitudinal observational study dedicated to advancing the understanding and treatment of Minimal Change Disease (MCD), Focal and Segmental Glomerulosclerosis (FSGS), IgA Nephropathy and Membranous Nephropathy (MN) in all age groups. It is different from NEPTUNE in that it includes prevalent patients (with a kidney biopsy within the last 5 years) and also includes patients with IgA Nephropahty. It is the largest cohort study in the history of glomerular disease research.
  • Inclusion:
    All ages with a kidney biopsy in the last 5 years showing Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), IgA Nephropathy and Membranous Nephropathy (MN); willingness to donate blood and urine during annual study visits
  • Exclusion:
    ESRD, Solid organ or bone marrow transplant at the time of first kidney biopsy; diagnosis of any of the following at the time of biopsy: diabetes mellitus, systemic lupus erythamatosus (SLE); active malignancy, except non-melanoma skin cancer; active hepatitis B or C infection, defined as a positive viral load

D-FINE: Vitamin D Supplementation in Glomerular Disease

  • Name of PI and Coordinator or Recruiter:
    • Jonathan Hogan, MD
    • Study Coordinator: Krishna Kallem
  • Contact:
    Krishna Kallem
    krishna.kallem@uphs.upenn.edu
    484-358-0315
  • Type of Study:
    Open label efficacy study on the effects of vitamin D on proteinuria in young patients (up to 30 years old) with FSGS
  • Inclusion:
    Ages 5-30 years, diagnosis of biopsy-proven FSGS, serum 25(OH)D level <20 ng/ml and urine protein:creatinine ratio ⩾0.5 at Screening Visit and no new immuno-modulatory agent within prior 3 months of Screening Visit (not including corticosteroid therapy).
  • Exclusion:
    Pregnancy, estimated Glomerular Filtration Rate (eGFR) <30 ml/min/1.73m2 at Screening Visit, serum phosphorus > 5.5 mg/dl or hypercalcemia, chronic medical conditions or medications unrelated to the renal disease that may impact vitamin D status, known history of kidney stone(s).

NEPTUNE (The Nephrotic Syndrome Study Network)

  • Name of PI and Coordinator or Recruiter:
    • Lawrence B. Holzman, MD
    • Jonathan Hogan, MD
    • Radhakrishna Kallem, MD, MPH
  • Contact:
    Krishna Kallem
    krishna.kallem@uphs.upenn.edu
    484-358-0315
  • Type of Study:
    Observational
  • Purpose of Study/Patient Population:
    The Nephrotic Syndrome Study Network (NEPTUNE) is a multi-disciplinary, multi-center longitudinal observational study dedicated to advancing the understanding and treatment of Minimal Change Disease (MCD), Focal and Segmental Glomerulosclerosis (FSGS), and Membranous Nephropathy (MN) in all age groups.
  • Inclusion:
    All ages with Suspected new diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN) BEFORE the biopsy. The subjects MUST be enrolled in the study before the biopsy and continuation in the study is subject to the biopsy results showing the target conditions. Documented urinary protein excretion ⩾500mg/24 hr or urine spot protein/creatinine ratio of ≥ 0.5.
  • Exclusion:
    Prior solid organ transplant; Clinical, Serological or histological evidence of systemic lupus erythematosus (SLE; Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia); Known systemic disease diagnosis at time of enrollment with life expectancy less than 6 months
Share This Page: